大血管闭塞性卒中患者静脉阿替普酶、早期再灌注与临床结局的关联:DIRECT-MT随机试验的事后分析
该研究是对DIRECT-MT随机试验的事后分析,纳入623例大血管闭塞卒中患者,评估静脉阿替普酶与早期再灌注(eTICI≥2a)及临床结局的关联。结果显示静脉阿替普酶独立关联早期再灌注(调整OR 2.06),且该效应受随机至腹股沟穿刺时间修饰。作者认为若预计血管内治疗延迟超过约半小时,应考虑静脉阿替普酶。
要点
- 早期再灌注与更好功能结局相关(调整OR 1.92)。
- 静脉阿替普酶独立关联早期再灌注(调整OR 2.06)。
- 随机至穿刺≤33分钟时阿替普酶效应不显著,>33分钟时调整OR 4.07。
核心结论
- 对于直接就诊于具备血管内治疗能力医院的大血管闭塞患者,当血管内治疗延迟超过约半小时时,静脉阿替普酶增加早期再灌注。
- 因此,若治疗团队预计血管内治疗会延迟,应考虑静脉阿替普酶。
研究设计与样本
- DIRECT-MT随机试验的事后分析,比较血管内治疗前静脉阿替普酶与单纯血管内治疗。
- 656例随机患者中623例有足够血管造影评估早期再灌注而被纳入。
主要发现
- 623例中317例接受静脉阿替普酶、306例未接受;91例(15%)发生早期再灌注。
- 早期再灌注者改良Rankin量表0-2分为49/91(54%),无早期再灌注者为178/531(34%);调整OR 1.92(95%CI 1.15-3.21),P<0.001。
- 静脉阿替普酶组早期再灌注59/317(19%),未接受组32/306(10%);调整OR 2.06(95%CI 1.27-3.33),P=0.003。
- 随机至腹股沟穿刺≤33分钟者调整OR 1.06(95%CI 0.53-2.10),>33分钟者调整OR 4.07(95%CI 1.86-8.86),交互作用P=0.012。
关键数值与推荐
- 早期再灌注定义为血管造影上扩大脑梗死溶栓评分(eTICI)≥2a。
- 随机至腹股沟穿刺时间按中位数33分钟二分。
临床怎么用
- 作者认为,若治疗团队预计血管内治疗会延迟,应考虑静脉阿替普酶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The added value of intravenous alteplase in reperfusing ischemic brain tissue in patients undergoing endovascular treatment and directly presented to an endovascular treatment-capable hospital is uncertain. We conducted this post hoc analysis of a randomized trial (DIRECT-MT [Direct Intraarterial Thrombectomy in Order to Revascularize Acute Ischemic Stroke Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals: A Multicenter Randomized Clinical Trial]) to explore the association of intravenous alteplase, early (preendovascular treatment) reperfusion, and clinical outcome and to determine factors which may modify alteplase treatment effect on early reperfusion. METHODS: In this post hoc analysis of the DIRECT-MT randomized trial comparing intravenous alteplase before endovascular treatment versus endovascular treatment only, 623 of 656 randomized patients, with adequate angiographic evaluation for early reperfusion assessment, were included. The association of intravenous alteplase and early reperfusion (defined as expanded Thrombolysis in Cerebral Infarction score ≥2a on angiogram) was assessed using unadjusted comparisons and multivariable logistic regression. RESULTS: Among 623 patients included (317 received intravenous alteplase and 306 did not), early reperfusion occurred in 91 (15%) patients and was associated with better functional outcome (modified Rankin Scale score, 0-2 of 49/91 [54%] versus 178/531 [34%]; adjusted odds ratio, 1.92 [95% CI, 1.15-3.21]; P<0.001). Intravenous alteplase was independently associated with early reperfusion (59/317 [19%] versus 32/306 [10%]; adjusted odds ratio, 2.06 [95% CI, 1.27-3.33]; P=0.003), and the alteplase effect was modified by time from randomization to groin puncture (dichotomized by median, ≤33 minutes; adjusted odds ratio, 1.06 [95% CI, 0.53-2.10] versus >33 minutes; adjusted odds ratio, 4.07 [95% CI, 1.86-8.86]; Pinteraction=0.012). CONCLUSIONS: For patients with large vessel occlusion directly presenting to an endovascular treatment-capable hospital, intravenous alteplase increases early reperfusion when endovascular treatment gets delayed more than approximately half an hour. Thus, intravenous alteplase should be considered if endovascular treatment delays are anticipated by the treating medical team. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03469206.
引用
- Zhou Y, Zhang L, Ospel J, et al. Association of Intravenous Alteplase, Early Reperfusion, and Clinical Outcome in Patients With Large Vessel Occlusion Stroke: Post Hoc Analysis of the Randomized DIRECT-MT Trial. Stroke. 2022. PMID: 35240861. doi:10.1161/STROKEAHA.121.037061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。